HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	CD4+/CD56+ hematodermic neoplasm, Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Skin and Connective Tissue Diseases, acute biphenotypic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, juvenile myelomonocytic leukemia, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mixed phenotype acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, skin disorder, skin neoplasm	Recruiting	Phase 1	2026-05-18		NCT03326921

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Fred Hutchinson Cancer Center	123
HighPass Bio, Inc.	1
PromiCell Therapeutics, Inc.	3

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Fred Hutch/University of Washington Cancer Consortium	Seattle	United States	140